Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with over 3 × 106deaths in 2019. Such an alarming figure becomes frightening when combined with the number of lost lives resulting from COVID-caused respiratory failure. Because COPD exacerbations identified early can commonly be treated at home, early symptom detections may enable a major reduction of COPD patient readmission and associated healthcare costs; this is particularly important during pandemics such as COVID-19 in which healthcare facilities are overwhelmed. The standard adjuncts used to assess lung function (e.g., spirometry, plethysmography, and CT scan) are expensive, time consuming, and cannot be used in remote patient monitoring of an acute exacerbation. In this paper, a wearable multi-modal system for breathing analysis is presented, which can be used in quantifying various airflow obstructions. The wearable multi-modal electroacoustic system employs a body area sensor network with each sensor-node having a multi-modal sensing capability, such as a digital stethoscope, electrocardiogram monitor, thermometer, and goniometer. The signal-to-noise ratio (SNR) of the resulting acoustic spectrum is used as a measure of breathing intensity. The results are shown from data collected from over 35 healthy subjects and 3 COPD subjects, demonstrating a positive correlation of SNR values to the health-scale score.
Identification of COVID-19 Type Respiratory Disorders Using Channel State Analysis of Wireless Communications Links
One deadly aspect of COVID-19 is that those infected can often be contagious before exhibiting overt symptoms. While methods such as temperature checks and sinus swabs have aided with early detection, the former does not always provide a reliable indicator of COVID-19, and the latter is invasive and requires significant human and material resources to administer. This paper presents a non-invasive COVID-19 early screening system implementable with commercial off-the-shelf wireless communications devices. The system leverages the Doppler radar principle to monitor respiratory-related chest motion and identifies breathing rates that indicate COVID-19 infection. A prototype was developed from software-defined radios (SDRs) designed for 5G NR wireless communications and system performance was evaluated using a robotic mover simulating human breathing, and using actual breathing, resulting in a consistent respiratory rate accuracy better than one breath per minute, exceeding that used in common medical practice.Clinical Relevance-This establishes the potential efficacy of wireless communications based radar for recognizing respiratory disorders such as COVID-19.
more »
« less
- NSF-PAR ID:
- 10312062
- Date Published:
- Journal Name:
- Annu Int Conf IEEE Eng Med Biol Soc
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
more » « less
-
Currently, wired respiratory rate sensors tether patients to a location and can potentially obscure their body from medical staff. In addition, current wired respiratory rate sensors are either inaccurate or invasive. Spurred by these deficiencies, we have developed the Bellyband, a less invasive smart garment sensor, which uses wireless, passive Radio Frequency Identification (RFID) to detect bio-signals. Though the Bellyband solves many physical problems, it creates a signal processing challenge, due to its noisy, quantized signal. Here, we present an algorithm by which to estimate respiratory rate from the Bellyband. The algorithm uses an adaptively parameterized Savitzky-Golay (SG) filter to smooth the signal. The adaptive parameterization enables the algorithm to be effective on a wide range of respiratory frequencies, even when the frequencies change sharply. Further, the algorithm is three times faster and three times more accurate than the current Bellyband respiratory rate detection algorithm and is able to run in real time. Using an off-the-shelf respiratory monitor and metronome-synchronized breathing, we gathered 25 sets of data and tested the algorithm against these trials. The algorithm’s respiratory rate estimates diverged from ground truth by an average Root Mean Square Error (RMSE) of 4.1 breaths per minute (BPM) over all 25 trials. Further, preliminary results suggest that the algorithm could be made as or more accurate than widely used algorithms that detect the respiratory rate of non-ventilated patients using data from an Electrocardiogram (ECG) or Impedance Plethysmography (IP).more » « less
-
Abstract Helmet continuous positive applied pressure is a form of noninvasive ventilation (NIV) that has been used to provide respiratory support to COVID-19 patients. Helmet NIV is low-cost, readily available, provides viral filters between the patient and clinician, and may reduce the need for invasive ventilation. Its widespread adoption has been limited, however, by the lack of a respiratory monitoring system needed to address known safety vulnerabilities and to monitor patients. To address these safety and clinical needs, we developed an inexpensive respiratory monitoring system based on readily available components suitable for local manufacture. Open-source design and manufacturing documents are provided. The monitoring system comprises flow, pressure, and CO2 sensors on the expiratory path of the helmet circuit and a central remote station to monitor up to 20 patients. The system is validated in bench tests, in human-subject tests on healthy volunteers, and in experiments that compare respiratory features obtained at the expiratory path to simultaneous ground-truth measurements from proximal sensors. Measurements of flow and pressure at the expiratory path are shown to deviate at high flow rates, and the tidal volumes reported via the expiratory path are systematically underestimated. Helmet monitoring systems exhibit high-flow rate, nonlinear effects from flow and helmet dynamics. These deviations are found to be within a reasonable margin and should, in principle, allow for calibration, correction, and deployment of clinically accurate derived quantities.more » « less
-
Background Limited data are available regarding the balance of risks and benefits from human milk and/or breastfeeding during and following maternal infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Objective To investigate whether SARS-CoV-2 can be detected in milk and on the breast after maternal coronavirus disease 2019 (COVID-19) diagnosis; and characterize concentrations of milk immunoglobulin (Ig) A specific to the SARS-CoV-2 spike glycoprotein receptor binding domain (RBD) during the 2 months after onset of symptoms or positive diagnostic test. Methods Using a longitudinal study design, we collected milk and breast skin swabs one to seven times from 64 lactating women with COVID-19 over a 2-month period, beginning as early as the week of diagnosis. Milk and breast swabs were analyzed for SARS-CoV-2 RNA, and milk was tested for anti-RBD IgA. Results SARS-CoV-2 was not detected in any milk sample or on 71% of breast swabs. Twenty-seven out of 29 (93%) breast swabs collected after breast washing tested negative for SARS-CoV-2. Detection of SARS-CoV-2 on the breast was associated with maternal coughing and other household COVID-19. Most (75%; 95% CI, 70-79%; n=316) milk samples contained anti-RBD IgA, and concentrations increased ( P =.02) during the first two weeks following onset of COVID-19 symptoms or positive test. Milk-borne anti-RBD IgA persisted for at least two months in 77% of women. Conclusion Milk produced by women with COVID-19 does not contain SARS-CoV-2 and is likely a lasting source of passive immunity via anti-RBD IgA. These results support recommendations encouraging lactating women to continue breastfeeding during and after COVID-19 illness.more » « less
-
The COVID-19 pandemic has changed the lives of many people around the world. Based on the available data and published reports, most people diagnosed with COVID-19 exhibit no or mild symptoms and could be discharged home for self-isolation. Considering that a substantial portion of them will progress to a severe disease requiring hospitalization and medical management, including respiratory and circulatory support in the form of supplemental oxygen therapy, mechanical ventilation, vasopressors, etc. The continuous monitoring of patient conditions at home for patients with COVID-19 will allow early determination of disease severity and medical intervention to reduce morbidity and mortality. In addition, this will allow early and safe hospital discharge and free hospital beds for patients who are in need of admission. In this review, we focus on the recent developments in next-generation wearable sensors capable of continuous monitoring of disease symptoms, particularly those associated with COVID-19. These include wearable non/minimally invasive biophysical (temperature, respiratory rate, oxygen saturation, heart rate, and heart rate variability) and biochemical (cytokines, cortisol, and electrolytes) sensors, sensor data analytics, and machine learning-enabled early detection and medical intervention techniques. Together, we aim to inspire the future development of wearable sensors integrated with data analytics, which serve as a foundation for disease diagnostics, health monitoring and predictions, and medical interventions.more » « less
- Free Publicly Accessible Full Text
-
Accepted Manuscript1.0
- Conference Paper:
- https://doi.org/10.1109/EMBC46164.2021.9630016
